Insomnia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Insomnia Market Outlook

Thelansis’s “Insomnia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Insomnia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Insomnia Overview

Insomnia is the most common clinical condition in which the person experiences difficulty sleeping and is subclassified as short-term, chronic, and other. Sometimes it is described as the presence of polysomnographic evidence of disturbed sleep. Therefore insomnia is considered to exist when there is long sleep latency, frequent nocturnal awakening, prolonged wakefulness throughout the sleep phase, or transient arousals. Insomnia can be a primary sleep disorder, comorbid sleep condition, and other mental or medical disorders. The etiology includes environmental, genetic, behavioral, and physiological factors culminating in hyperarousal. Insomnia is the complex interaction between cognitive arousal, altered circulation, and the homeostatic system. Decreased function of the sleep-walk switch may also contribute to insomnia. During sleep, there is a gradual shift from non-rapid-eye movement (non-REM) sleep to rapid-eye-movement (REM) sleep. The most common symptom was trouble sustaining sleep(61%), followed by early morning awakening(2.2%), difficulties beginning sleep(7.7%), and nonrestorative sleep (7.7%). The American Academy of Sleep Medicine divides rest into five stages: Stage W (wakefulness), Stage N1 (relaxed wakefulness), Stage N2 (light sleep), Stage N3 (deep or slow-wave sleep), and Stage R (REM sleep or dreaming). N1-N3 are non-REM sleep stages with minimal cortical activity, whereas REM sleep has significant cortical activity.

• In the U.S., approximately 30% to 40% of adults have insomnia. Short-term insomnia has an estimated prevalence of 9.5%, and 1 in 5 cases of short-term insomnia progresses to chronic insomnia. People with poor health or impaired quality of life are more likely to suffer from insomnia (QOL).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: